Open AccessIncreasing the biological activity of benzimidazoles based on the supramolecular nanoscale delivery system with licorice extract against helminthiasis
Author(s) -
A. I. Varlamova,
И. А. Архипов,
С. С. Халиков,
М. В. Арисов,
К. М. Садов,
А. В. Душкин
Publication year - 2020
Publication title -
iop conference series. earth and environmental science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.179
H-Index - 26
eISSN - 1755-1307
pISSN - 1755-1315
DOI - 10.1088/1755-1315/548/4/042012
Subject(s) - albendazole , anthelmintic , oxfendazole , pharmacology , medicine , veterinary medicine , surgery , fenbendazole
This paper considers the effect of mechanochemical technology on the anthelmintic efficacy of a solid dispersion (SD) of albendazole (ABZ) with licorice extract (LE) / SDALE/, which is considered as a means of targeted delivery. SDALE tests were carried out on white mice experimentally infected with Trichinella spiralis and Hymenolepis nana and on sheep naturally infected with gastrointestinal strongylates and Moniezia expansa cestodes. For each helminthiasis, animals of different groups of 9–12 in each were orally administered once a dose of SDALE of 2.0 mg/kg of active substance (AS) in the form of 10–20 % powders and 1 and 2% suspensions in comparison with the basic drug - a substance of albendazole at the dose of 2.0 mg/kg. SDALE is prepared by joint milling of similar components (ABZ and LE) in grinders with adjustable immersion energy (module, time, weight ratio of components, drum rotation speed) for 2 hours. Animals of the control groups did not receive the drug. The activity of the drugs was determined according to the data of coproovoscopic examination of sheep by flotation method before and 15 days after treatment. SDALE at the dose of 2.0 mg/kg of AS in the form of 10 and 20% powders and 1 and 2% suspensions showed respectively 91.4; 89.3; 87.2 and 92.3% efficacy against Nematodirus spp. and 90.7; 88.4; 87.4 and 91.2% activity against other types of Strongylata when receiving a 23.2 and 22.7% effect of the base drug - ABZ.